Methods for purifying trans-(−)-Δ
Methods for making trans-(−)-Δ 9 -tetrahydrocannabinol and trans-(+)-Δ 9 -tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ 9 -tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-Δ 9 )-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ 9 -tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of trans-(−)-Δ 9 -tetrahydrocannabinol and trans-(+)-Δ 9 -tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(−)-Δ 9 -tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.
1. A method for treating emesis, comprising administering to a patient in need thereof an effective amount of a trans-(−)-Δ 9 -tetrahydrocannabinol composition comprising at least 99.0% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol and less than 0.05% of Δ 9 -tetrahydrocannabinol acid based on the total amount of cannabinoids.
2. A method for treating loss of appetite, comprising administering to a patient in need thereof an effective amount of a trans-(−)-Δ 9 -tetrahydrocannabinol composition comprising at least 99.0% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol and less than 0.05% of Δ 9 -tetrahydrocannabinol acid based on the total amount of cannabinoids.
3. A method for treating weight loss, comprising administering to a patient in need thereof an effective amount of a trans-(−)-Δ 9 -tetrahydrocannabinol composition comprising at least 99.0% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol and less than 0.05% of Δ 9 -tetrahydrocannabinol acid based on the total amount of cannabinoids.
4. A method for treating pain, comprising administering to a patient in need thereof an effective amount of a trans-(−)-Δ 9 -tetrahydrocannabinol composition comprising at least 99.0% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol and less than 0.05% of Δ 9 -tetrahydrocannabinol acid based on the total amount of cannabinoids.
5. The method for treating emesis of claim 1 , wherein the trans-(−)Δ 9 -tetrahydrocannabinol composition comprises at least 99.5% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.
6. The method for treating emesis of claim 1 , wherein the trans-(−)-Δ 9 -tetrahydrocannabinol composition comprises at least 99.9% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.
7. The method for treating emesis of claim 1 , wherein the trans-(−)-Δ 9 -tetrahydrocannabinol composition comprises at least 99.95% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.
8. The method for treating emesis of claim 1 , wherein the trans-(−)-Δ 9 -tetrahydrocannabinol composition comprises at least 99.98% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.
9. The method for treating loss of appetite of claim 2 , wherein the trans-(−)-Δ 9 -tetrahydrocannabinol composition comprises at least 99.5% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.
10. The method for treating loss of appetite of claim 2 , wherein the trans-(−)-Δ 9 -tetrahydrocannabinol composition comprises at least 99.9% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.
11. The method for treating loss of appetite of claim 2 , wherein the trans-(−)-Δ 9 -tetrahydrocannabinol composition comprises at least 99.95% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.
12. The method for treating loss of appetite of claim 2 , wherein the trans-(−)-Δ 9 -tetrahydrocannabinol composition comprises at least 99.98% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.
13. The method for treating weight loss of claim 3 , wherein the trans-(−)-Δ 9 -tetrahydrocannabinol composition comprises at least 99.5% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.
14. The method for treating weight loss of claim 3 , wherein the trans-(−)-Δ 9 -tetrahydrocannabinol composition comprises at least 99.9% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.
15. The method for treating weight loss of claim 3 , wherein the trans-(−)-Δ 9 -tetrahydrocannabinol composition comprises at least 99.95% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.
16. The method for treating weight loss of claim 3 , wherein the trans-(−)-Δ 9 -tetrahydrocannabinol composition comprises at least 99.98% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.
17. The method for treating pain of claim 4 , wherein the trans-(−)-Δ 9 -tetrahydrocannabinol composition comprises at least 99.5% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.
18. The method for treating pain of claim 4 , wherein the trans-(−)-Δ 9 -tetrahydrocannabinol composition comprises at least 99.9% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.
19. The method for treating pain of claim 4 , wherein the trans-(−)-Δ 9 -tetrahydrocannabinol composition comprises at least 99.95% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.
20. The method for treating pain of claim 4 , wherein the trans-(−)Δ 9 -tetrahydrocannabinol composition comprises at least 99.98% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.